Ofloxacin otic solution
Alternative Names: 0.3% Ofloxacin otic solution - Daiichi; DL 8280; Floxin Otic; Floxin Otic SINGLESLatest Information Update: 25 Sep 2021
At a glance
- Originator Daiichi Sankyo Company
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Otitis externa; Otitis media
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 10 May 2004 Daiichi has launched Floxin® Otic SINGLES™ for common ear infections in the USA
- 01 Mar 2004 Registered for Otitis externa in USA (once-daily for 7 days)